Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Screening for Lynch Syndrome in Young Colorectal Cancer Patients from Saudi Arabia Using Microsatellite Instability as the Initial Test.

Alqahtani M, Grieu F, Carrello A, Amanuel B, Mashour M, Alattas R, Alsaleh K, Alsheikh A, Alqahtani S, Iacopetta B.

Asian Pac J Cancer Prev. 2016;17(4):1917-23.

2.

KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at?

Scott RJ, Fox SB, Desai J, Grieu F, Amanuel B, Garrett K, Harraway J, Cheetham G, Pattle N, Haddad A, Byron K, Rudzki B, Waring P, Iacopetta B.

Asia Pac J Clin Oncol. 2014 Sep;10(3):261-5. doi: 10.1111/ajco.12201. Epub 2014 May 9.

PMID:
24811330
3.

Population-based screening for Lynch syndrome in Western Australia.

Schofield L, Grieu F, Amanuel B, Carrello A, Spagnolo D, Kiraly C, Pachter N, Goldblatt J, Platell C, Levitt M, Stewart C, Salama P, Ee H, Raftopoulous S, Katris P, Threlfall T, Edkins E, Wallace M, Iacopetta B.

Int J Cancer. 2014 Sep 1;135(5):1085-91. doi: 10.1002/ijc.28744. Epub 2014 Feb 24.

4.

A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma.

Richter A, Grieu F, Carrello A, Amanuel B, Namdarian K, Rynska A, Lucas A, Michael V, Bell A, Fox SB, Hewitt CA, Do H, McArthur GA, Wong SQ, Dobrovic A, Iacopetta B.

Sci Rep. 2013;3:1659. doi: 10.1038/srep01659.

5.

Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region.

Amanuel B, Grieu F, Kular J, Millward M, Iacopetta B.

Pathology. 2012 Jun;44(4):357-9. doi: 10.1097/PAT.0b013e3283532565.

PMID:
22614711
6.

A state-wide population-based program for detection of lynch syndrome based upon immunohistochemical and molecular testing of colorectal tumours.

Schofield L, Grieu F, Goldblatt J, Amanuel B, Iacopetta B.

Fam Cancer. 2012 Mar;11(1):1-6. doi: 10.1007/s10689-011-9494-2.

PMID:
22120844
7.

Microsatellite instability in colorectal cancer.

Iacopetta B, Grieu F, Amanuel B.

Asia Pac J Clin Oncol. 2010 Dec;6(4):260-9. doi: 10.1111/j.1743-7563.2010.01335.x. Epub 2010 Oct 26. Review.

PMID:
21114775
8.

KRAS mutation and microsatellite instability in endometrial adenocarcinomas showing MELF-type myometrial invasion.

Stewart CJ, Amanuel B, Grieu F, Carrello A, Iacopetta B.

J Clin Pathol. 2010 Jul;63(7):604-8. doi: 10.1136/jcp.2009.069500.

PMID:
20591910
9.

Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features.

Ang PW, Loh M, Liem N, Lim PL, Grieu F, Vaithilingam A, Platell C, Yong WP, Iacopetta B, Soong R.

BMC Cancer. 2010 May 21;10:227. doi: 10.1186/1471-2407-10-227.

10.

A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting.

Whitehall V, Tran K, Umapathy A, Grieu F, Hewitt C, Evans TJ, Ismail T, Li WQ, Collins P, Ravetto P, Leggett B, Salto-Tellez M, Soong R, Fox S, Scott RJ, Dobrovic A, Iacopetta B.

J Mol Diagn. 2009 Nov;11(6):543-52. doi: 10.2353/jmoldx.2009.090057. Epub 2009 Oct 8.

11.

The MTHFR C677T and DeltaDNMT3B C-149T polymorphisms confer different risks for right- and left-sided colorectal cancer.

Iacopetta B, Heyworth J, Girschik J, Grieu F, Clayforth C, Fritschi L.

Int J Cancer. 2009 Jul 1;125(1):84-90. doi: 10.1002/ijc.24324.

12.

Population-based detection of Lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test.

Schofield L, Watson N, Grieu F, Li WQ, Zeps N, Harvey J, Stewart C, Abdo M, Goldblatt J, Iacopetta B.

Int J Cancer. 2009 Mar 1;124(5):1097-102. doi: 10.1002/ijc.23863.

13.

Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.

Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B.

J Clin Oncol. 2009 Jan 10;27(2):186-92. doi: 10.1200/JCO.2008.18.7229. Epub 2008 Dec 8.

PMID:
19064967
14.

Heterogeneous staining for mismatch repair proteins during population-based prescreening for hereditary nonpolyposis colorectal cancer.

Watson N, Grieu F, Morris M, Harvey J, Stewart C, Schofield L, Goldblatt J, Iacopetta B.

J Mol Diagn. 2007 Sep;9(4):472-8. Epub 2007 Jul 25.

15.

Methylation levels of LINE-1 repeats and CpG island loci are inversely related in normal colonic mucosa.

Iacopetta B, Grieu F, Phillips M, Ruszkiewicz A, Moore J, Minamoto T, Kawakami K.

Cancer Sci. 2007 Sep;98(9):1454-60. Epub 2007 Jul 19.

16.

APC gene methylation is inversely correlated with features of the CpG island methylator phenotype in colorectal cancer.

Iacopetta B, Grieu F, Li W, Ruszkiewicz A, Caruso M, Moore J, Watanabe G, Kawakami K.

Int J Cancer. 2006 Nov 15;119(10):2272-8.

17.

BRAF mutation and gene methylation frequencies of colorectal tumours with microsatellite instability increase markedly with patient age.

Iacopetta B, Li WQ, Grieu F, Ruszkiewicz A, Kawakami K.

Gut. 2006 Aug;55(8):1213-4. No abstract available.

18.

DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer.

Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Grieu F, Watanabe G, Iacopetta B.

Br J Cancer. 2006 Feb 27;94(4):593-8.

19.

PIK3CA mutations in breast cancer are associated with poor outcome.

Li SY, Rong M, Grieu F, Iacopetta B.

Breast Cancer Res Treat. 2006 Mar;96(1):91-5. Epub 2005 Nov 30.

PMID:
16317585
20.

Gastrointestinal stromal tumours (GISTs): a clinicopathological and molecular study of 66 cases.

Koay MH, Goh YW, Iacopetta B, Grieu F, Segal A, Sterrett GF, Platten M, Spagnolo DV.

Pathology. 2005 Feb;37(1):22-31.

PMID:
15875730
21.

Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype.

Grieu F, Li WQ, Iacopetta B.

Breast Cancer Res Treat. 2004 Dec;88(3):197-204.

PMID:
15609121
22.

Screening for defective DNA mismatch repair in stage II and III colorectal cancer patients.

Chai SM, Zeps N, Shearwood AM, Grieu F, Charles A, Harvey J, Goldblatt J, Joseph D, Iacopetta B.

Clin Gastroenterol Hepatol. 2004 Nov;2(11):1017-25.

PMID:
15551255
23.
24.
25.

Development of a rapid genotyping method for single nucleotide polymorphisms and its application in cancer studies.

Grieu F, Joseph D, Norman P, Iacopetta B.

Oncol Rep. 2004 Feb;11(2):501-4.

PMID:
14719090
26.

Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers.

Grieu F, Malaney S, Ward R, Joseph D, Iacopetta B.

Anticancer Res. 2003 Sep-Oct;23(5b):4257-9.

PMID:
14666635
27.

Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer.

Wang C, van Rijnsoever M, Grieu F, Bydder S, Elsaleh H, Joseph D, Harvey J, Iacopetta B.

Oncology. 2003;64(3):259-65.

PMID:
12697967
28.

Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands.

van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, Iacopetta B.

Gut. 2002 Dec;51(6):797-802.

29.

Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer.

Powell BL, van Staveren IL, Roosken P, Grieu F, Berns EM, Iacopetta B.

Carcinogenesis. 2002 Feb;23(2):311-5.

PMID:
11872638
30.

Prognostic value of TP53 gene mutation in adjuvant treated breast cancer patients.

Powell BL, Bydder S, Grieu F, Gnanasampanthan G, Elsaleh H, Seshadri R, Berns EM, Iacopetta B.

Breast Cancer Res Treat. 2001 Sep;69(1):65-8.

PMID:
11759829
32.

P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma.

Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D, Iacopetta B.

Clin Cancer Res. 2001 May;7(5):1343-9.

33.

Can p53 alterations be used to predict tumour response to pre-operative chemo-radiotherapy in locally advanced rectal cancer?

Elsaleh H, Robbins P, Joseph D, Powell B, Grieu F, Menso L, Iacopetta B.

Radiother Oncol. 2000 Aug;56(2):239-44.

PMID:
10927144
34.

Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer.

Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B.

Lancet. 2000 May 20;355(9217):1745-50.

PMID:
10832824
35.
36.
37.

P53 alterations have no prognostic or predictive significance in Dukes' C rectal carcinomas.

Elsaleh H, Soontrapornchai P, Grieu F, Joseph D, Iacopetta B.

Int J Oncol. 1999 Dec;15(6):1239-43.

PMID:
10568834
38.

p53 protein overexpression is a prognostic indicator of poor survival in stage I endometrial carcinoma.

Powell B, Soong R, Grieu F, Knowles S, Hammond I, Iacopetta B.

Int J Oncol. 1999 Jan;14(1):175-9.

PMID:
9863026
39.
40.

p53 alterations are associated with improved prognosis in distal colonic carcinomas.

Soong R, Grieu F, Robbins P, Dix B, Chen D, Parsons R, House A, Iacopetta B.

Clin Cancer Res. 1997 Aug;3(8):1405-11.

41.

Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas.

Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, Williams KE, Turbett GR, House AK, Iacopetta BJ.

Hum Pathol. 1996 Oct;27(10):1050-5.

PMID:
8892589
42.

p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma.

Lim BH, Soong R, Grieu F, Robbins PD, House AK, Iacopetta BJ.

Int J Cancer. 1996 Jun 21;69(3):200-4.

43.

Epidermal growth factor in human and bovine milk.

Iacopetta BJ, Grieu F, Horisberger M, Sunahara GI.

Acta Paediatr. 1992 Apr;81(4):287-91.

PMID:
1606385
44.

Characterization of 3-methylcholanthrene effects on the rat glucocorticoid receptor in vivo.

Sunahara GI, Guenat C, Grieu F.

Cancer Res. 1989 Jul 1;49(13):3535-41.

Supplemental Content

Support Center